Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is simvastatin cost-effective for reducing the risk of vascular events?

Nature Clinical Practice Neurology volume 1, pages 86–87 (2005)Cite this article

boxed-textMihaylova B et al. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. Lancet 365: 1779–1785

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Russell LB et al. (1996) The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1172–1177

    Article  CAS  Google Scholar 

  2. Kassirer JP and Angell M (1994) The journal's policy on cost-effectiveness analyses. N Engl J Med 331: 669–670

    Article  CAS  Google Scholar 

  3. Taylor TN et al. (1996) Lifetime cost of stroke in the United States. Stroke 27: 1459–1466

    Article  CAS  Google Scholar 

  4. Hickenbottom SL et al. (2002) A national study of the quantity and cost of informal caregiving for the elderly with stroke. Neurology 58: 1754–1759

    Article  CAS  Google Scholar 

  5. Samsa GP et al. (1999) Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 52: 259–271

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine (Neurology), Director of the Duke Center for Cerebrovascular Disease and a Senior Fellow in the Center for Clinical Health Policy Research at Duke University and the Durham VA Medical Center, NC, USA

    Larry B Goldstein

Authors
  1. Larry B Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry B Goldstein.

Ethics declarations

Competing interests

Steering Committee and consultant for Pfizer-Parke-Davis-sponsored SPARCL Trial.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldstein, L. Is simvastatin cost-effective for reducing the risk of vascular events?. Nat Rev Neurol 1, 86–87 (2005). https://doi.org/10.1038/ncpneuro0036

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0036

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing